According to Zhitong Finance APP, luoxin pharmaceuticals group stock (002793.SZ) announced that its subsidiary, shandong luoxin pharmaceuticals group stock, has received the approval and issuance of a pharmaceutical registration certificate with the indication of "eradication of Helicobacter pylori with appropriate antibiotics" for its tegorla tablets by the National Medical Products Administration.

It is reported that tegorla tablet is a Potassium-Competitive Acid Blocker (P-CAB), which inhibits acid secretion by competitively binding to the potassium-binding site of the H+/K+-ATPase (proton pump) in the parietal cells. Unlike proton pump inhibitors (PPIs), P-CAB can directly inhibit H+/K+-ATPase without the need for activation in an acidic environment. Moreover, whether H+/K+-ATPase is activated or not, P-CAB can still bind to it. When used in combination with antibiotics, P-CAB creates the optimal pH environment for antibiotic eradication of Helicobacter pylori through its acid-suppressing effect.

The company has always had strong market competitiveness in the field of digestion. With the newly approved indication for tegorla tablets, it will provide a new and effective treatment option for patients infected with Hp, reducing the risk of developing gastric cancer and other diseases, thus alleviating the burden of societal diseases.